Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer [0.03%]
预测生物标志物指导局部晚期肺癌靶向治疗策略的影响因素
Francesca Cottini,Tim Lautenschlaeger
Francesca Cottini
Lung cancer accounts for the majority of cancer-related deaths worldwide. We sought out to summarize the current state of molecular predictors for response and toxicity in locally advanced lung cancer. Several changes have been introduced i...
Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies [0.03%]
局部晚期肺癌:疫苗及其他免疫治疗的最佳应用领域
Puneeth Iyengar,David E Gerber
Puneeth Iyengar
Lung cancer has traditionally been considered relatively resistant to immunotherapies. However, recent advances in the understanding of tumor-associated antigens, anti-tumor immune responses, and tumor immunosuppression mechanisms have resu...
Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment [0.03%]
肺癌治疗中膜磷脂、EML4-ALK和HSP90的新靶点
Andrei Laszlo,Dinesh Thotala,Dennis E Hallahan
Andrei Laszlo
Approximately one third of patients with non-small cell lung cancer have unresectable stage IIIA or stage IIIB disease; combined cytotoxic chemotherapy and radiation therapy delivered concurrently has been established as the standard treatm...
Management of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung) [0.03%]
与放化疗相关的正常组织毒性管理(主要针对皮肤、食管和肺)
Victor Y Yazbeck,Liza Villaruz,Marsha Haley et al.
Victor Y Yazbeck et al.
Nearly one quarter of patients with lung cancer present with locally advanced disease where concurrent chemoradiotherapy is the current standard of care for patients with good performance status. Cisplatin-based concurrent chemoradiotherapy...
Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer [0.03%]
局部晚期非小细胞肺癌确定性、术前或术后化学放射治疗
Josephine Feliciano,Steven Feigenberg,Minesh Mehta
Josephine Feliciano
Over the last few decades, the integration of chemotherapy and radiation has played a crucial role in the management of locally advanced non-small cell lung cancer (NSCLC). Locally advanced NSCLC is a very heterogeneous disease. Because of ...
Jessica S Donington,Harvey I Pass
Jessica S Donington
Treatment for locally advanced non-small cell lung cancer is complex. It may best be described as chemotherapy-based multimodality therapy, but there is little consensus on the optimal approach for local therapy. With the integration of the...
Advanced imaging (positron emission tomography and magnetic resonance imaging) and image-guided biopsy in initial staging and monitoring of therapy of lung cancer [0.03%]
正电子发射断层扫描和磁共振成像以及影像引导活检在肺癌初始分期及监测治疗中的应用
Shaheen Islam,Ronald C Walker
Shaheen Islam
The results of the National Lung Screening Trial strongly support early detection and definitive treatment to reduce lung cancer mortality. Once lung cancer is discovered, accurate staging at baseline is imperative to maximize patient benef...
Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer [0.03%]
肺癌放化疗治疗抵抗的基本机制
Henning Willers,Christopher G Azzoli,Wil L Santivasi et al.
Henning Willers et al.
In recent years, there have been multiple breakthroughs in our understanding of lung cancer biology. Despite significant advances in molecular targeted therapies, DNA-damaging cytotoxic therapies will remain the mainstay of lung cancer mana...
David P Carbone,Arnab Chakravarti
David P Carbone
Is interleukin 2 the best initial therapy for many patients with metastatic renal cell carcinoma? [0.03%]
IL-2是否是多数转移性肾细胞癌患者初始治疗的最佳选择?
George Philips,Michael B Atkins
George Philips